Search
Pennsylvania Paid Clinical Trials
A listing of 3293 clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2557 - 2568 of 3293
Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Recruiting
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Recruiting
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to:
* Learn how well the combination of tucatinib and Doxil works
* Learn more about the side effects of the combination of tucatinib and Doxil
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Alliance Cancer Specialists, Bensalem, Pennsylvania
Conditions: Breast Cancer
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Recruiting
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Merkel Cell Carcinoma
Persona Revision Knee System Outcomes
Recruiting
The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine/ Lancaster General Health, Lancaster, Pennsylvania
Conditions: Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Allegheny General Hospital - ASRI, Pittsburgh, Pennsylvania
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
Recruiting
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Dilated Cardiomyopathy, Heart Failure, Heart Disease
Hypofractionated WPPT With HDR Boost
Recruiting
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
Recruiting
This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are:
1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors,
2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional m... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/28/2025
Locations: Penn Prevention (Site ID: 30310), Philadelphia, Pennsylvania
Conditions: HIV Infections
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Recruiting
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pancreatic Carcinoma
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
Recruiting
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Gastrointestinal Stromal Tumors, GIST
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/28/2025
Locations: University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania
Conditions: Prostate Cancer
NIH R01 Friend to Friend With Coaching
Recruiting
This study examines the effectiveness of the Friend to Friend (F2F) program when conducted by teachers and counselors with active coaching from the research team. The project involves 14 small group sessions for relationally aggressive girls and 8 classroom sessions. Students, teachers, counselors and parents at intervention and control schools fill out pre- and post- program questionnaires.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Aggression
